曲美替尼
威罗菲尼
达布拉芬尼
医学
神经节胶质瘤
癌症研究
MEK抑制剂
肿瘤科
内科学
黑色素瘤
MAPK/ERK通路
癫痫
转移性黑色素瘤
激酶
生物
精神科
细胞生物学
作者
Asher Marks,Ranjit S. Bindra,Michael L. DiLuna,Anita Hüttner,Vikram Jairam,Kristopher T. Kahle,Mark W. Kieran
摘要
Abstract Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials. Monotherapy with vemurafenib has been associated with significant side effects, including rashes, papillomas, and squamous cell carcinomas. Here we describe an adolescent female with anaplastic ganglioglioma and significant skin reaction to vemurafenib with subsequent tumor response and tolerance to the BRAF/MEK inhibitor combination of dabrafenib and trametinib without recurrence of previous reaction.
科研通智能强力驱动
Strongly Powered by AbleSci AI